PL2726470T3 - Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych - Google Patents

Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych

Info

Publication number
PL2726470T3
PL2726470T3 PL12737238T PL12737238T PL2726470T3 PL 2726470 T3 PL2726470 T3 PL 2726470T3 PL 12737238 T PL12737238 T PL 12737238T PL 12737238 T PL12737238 T PL 12737238T PL 2726470 T3 PL2726470 T3 PL 2726470T3
Authority
PL
Poland
Prior art keywords
thiadiazol
treatment
neurodegenerative diseases
derivatives useful
ylpiperazine
Prior art date
Application number
PL12737238T
Other languages
English (en)
Inventor
Gerard Griffioen
Matthias Nettekoven
Katrien Princen
Hasane Ratni
Walter Vifian
Original Assignee
Remynd Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remynd Nv filed Critical Remynd Nv
Publication of PL2726470T3 publication Critical patent/PL2726470T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PL12737238T 2011-07-01 2012-06-29 Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych PL2726470T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11172324 2011-07-01
PCT/EP2012/062778 WO2013004642A1 (en) 2011-07-01 2012-06-29 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases
EP20120737238 EP2726470B1 (en) 2011-07-01 2012-06-29 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
PL2726470T3 true PL2726470T3 (pl) 2015-09-30

Family

ID=46545347

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12737238T PL2726470T3 (pl) 2011-07-01 2012-06-29 Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych

Country Status (10)

Country Link
US (1) US9023852B2 (pl)
EP (1) EP2726470B1 (pl)
JP (1) JP5972367B2 (pl)
CN (1) CN103619825B (pl)
AU (1) AU2012280420B2 (pl)
CA (1) CA2837247C (pl)
ES (1) ES2540956T3 (pl)
HK (1) HK1192726A1 (pl)
PL (1) PL2726470T3 (pl)
WO (1) WO2013004642A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744798B1 (en) * 2011-08-17 2016-03-30 reMynd NV Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
US10562869B2 (en) 2014-03-17 2020-02-18 Remynd Nv Oxadiazole compounds
CN109561680B (zh) * 2016-06-23 2021-07-13 圣朱德儿童研究医院 泛酸激酶的小分子调节剂
WO2018081167A1 (en) * 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
SG11202006047RA (en) 2017-12-27 2020-07-29 St Jude Childrens Res Hospital Inc Small molecule modulators of pantothenate kinases
WO2019133632A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Methods of treating disorders associated with castor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361179A1 (en) * 1999-03-03 2000-09-08 American Home Products Corporation New diazole derivatives as serotonergic agents
JP2002543070A (ja) * 1999-04-26 2002-12-17 ニューロサーチ、アクティーゼルスカブ ヘテロアリールジアザシクロアルカン類、その製造方法及びその使用方法
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine
WO2007005510A1 (en) * 2005-06-30 2007-01-11 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
JP2009526059A (ja) * 2006-02-07 2009-07-16 ワイス 11−ベータhsd1阻害剤
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases

Also Published As

Publication number Publication date
AU2012280420A1 (en) 2013-12-12
HK1192726A1 (en) 2014-08-29
EP2726470A1 (en) 2014-05-07
CA2837247C (en) 2020-03-31
JP2014518240A (ja) 2014-07-28
US9023852B2 (en) 2015-05-05
CN103619825B (zh) 2015-10-14
ES2540956T3 (es) 2015-07-15
EP2726470B1 (en) 2015-04-29
WO2013004642A1 (en) 2013-01-10
US20140128404A1 (en) 2014-05-08
CA2837247A1 (en) 2013-01-10
CN103619825A (zh) 2014-03-05
JP5972367B2 (ja) 2016-08-17
AU2012280420B2 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
HRP20190491T1 (hr) Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HRP20181950T1 (hr) Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
SI2838539T1 (sl) Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201308176B (en) Therapeutic treatment
HK1208454A1 (zh) 治療細菌性疾病的嘧啶衍生物
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
EP2736439A4 (en) CLASS 1 LASER TREATMENT SYSTEM